



**Physician Worksheet for Prostate Cancer
Medicare Advantage Prior Authorization Request**

Prior Authorization for Therapeutic Radiation Procedures Including Intensity Modulation Radiation Treatment (IMRT), Stereotactic Radio Surgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)

This worksheet is a tool to help you identify and collect the clinical information required to support a prior authorization request for UnitedHealthcare Medicare Advantage members. After the clinician completes the clinical information, please go to UHCprovider.com > Prior Authorization and Notification > Oncology > Medicare Advantage Therapeutic Radiation to submit the prior authorization request. Submitting the clinical information from this worksheet alone won't automatically result in prior authorization approval; additional clinical information may be requested during the clinical review process. If you have questions about your submission or need to request an expedited review, please call 866-889-8054.

Patient/ Member	First Name:	Middle Initial:	Last Name:
	DOB (mm/dd/yyyy):		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female
	Health Plan:		Member ID:

Clinical Information	ICD-10 Code(s):		
	What is the radiation therapy treatment start date (mm/dd/yyyy)?		
	<i>Please have the answers to below questions prepared as these questions may be asked.</i>		
	Is radiation being delivered as:		
	<input type="checkbox"/> Initial treatment for a newly diagnosed prostate cancer without distant metastatic disease <input type="checkbox"/> Post-prostatectomy adjuvant therapy due to adverse pathology without distant metastatic disease <input type="checkbox"/> Post-prostatectomy salvage therapy due to recurrence without distant metastatic disease <input type="checkbox"/> Palliative therapy (i.e. non-curative therapy to alleviate obstructive symptoms or bleeding) <input type="checkbox"/> Other (e.g. Recurrent prostate cancer, Definitive treatment of prostate in the metastatic setting)		
	What was the T stage at initial diagnosis?		
	<input type="checkbox"/> T0 <input type="checkbox"/> T2a <input type="checkbox"/> T3a <input type="checkbox"/> T1a <input type="checkbox"/> T2b <input type="checkbox"/> T3b <input type="checkbox"/> T1b <input type="checkbox"/> T2c <input type="checkbox"/> T4 <input type="checkbox"/> T1c		
	Has the cancer spread to any of the regional lymph nodes (N1 disease)? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A		
	What is the patient's PSA level (ng/mL)? _____ng/mL		
	What is/was the patient's Gleason score (range: 2 to 10)?		
	<input type="checkbox"/> <= 6 <input type="checkbox"/> 8 <input type="checkbox"/> 3 + 4 = 7 <input type="checkbox"/> 9 or 10 <input type="checkbox"/> 4 + 3 = 7 <input type="checkbox"/> Unknown		
	If high or very high risk, will the pelvic lymph nodes be treated? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A		
	What treatment technique will be used?		
<input type="checkbox"/> Hypofractionated Intensity Modulated Radiation Therapy (IMRT) <input type="checkbox"/> Conventionally fractionated Intensity Modulated Radiation Therapy (IMRT) <input type="checkbox"/> Stereotactic Body Radiation Therapy (SBRT)			

Clinical Information	Additional Comments/Information: